Table 2.
Univariate and multivariate analysis of OS.
| Characteristics | PFS | OS | ||||
|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||
| p value | HR (95% CI) | p value | p value | HR (95% CI) | p value | |
| Age ≥ 65 vs. < 65 |
0.81 | 0.76 (0.48-1.19) | 0.23 | 0.41 | 0.95 (0.57-1.59) | 0.84 |
| Gender Male vs. Female |
0.1 | 1.46 (0.95-2.23) | 0.08 | 0.04 | 2.05 (1.24-3.37) | 0.005 |
| ECOG PS ≥ 2 vs. 0-1 |
0.004 | 1.82 (1.06-3.12) | 0.03 | < 0.0001 | 2.69 (1.48-4.91) | 0.001 |
| CCr (mL/min) < 60 vs. ≥ 60 |
0.31 | 0.74 (0.45-1.23) | 0.24 | 0.4 | 0.74 (0.40-1.25) | 0.27 |
| Primary site Bladder vs. upper tract |
0.55 | 0.88 (0.56-1.38) | 0.56 | 0.56 | 1.03 (0.62-1.70) | 0.92 |
| Histologic variant Yes vs. No |
0.33 | 1.56 (1.00-2.42) | 0.05 | 0.57 | 1.47 (0.88-2.43) | 0.14 |
| Visceral metastasis Yes vs. No |
< 0.0001 | 1.90 (1.22-2.98) | 0.005 | < 0.0001 | 1.91 (1.21-3.02) | 0.006 |
| WBC (× 103/μL) ≥ 10000 vs < 10000 |
0.08 | 1.37 (0.85-2.19) | 0.19 | 0.05 | 1.44 (0.85-2.44) | 0.18 |
| Hb (g/dL) < 10 vs. ≥ 10 |
0.32 | 0.63 (0.35-1.14) | 0.13 | 0.09 | 0.84 (0.44-1.58) | 0.58 |
| PNI < 40 vs. ≥ 40 |
0.001 | 1.66 (0.96-2.87) | 0.07 | < 0.0001 | 2.28 (1.31-3.96) | 0.003 |
| 1st line chemotherapy Carboplatin vs. Cisplatin |
0.16 | 1.63 (0.96-2.76) | 0.07 | 0.13 | 1.68 (0.93-3.03) | 0.09 |
Abbreviation: CCr, clearance of creatinine; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio;
OS, overall survival; PFS, progression-free survival; PNI, prognostic nutritional index; PS, performance status; WBC, white blood cell count